1. Home
  2. DLO vs DNLI Comparison

DLO vs DNLI Comparison

Compare DLO & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DLocal Limited

DLO

DLocal Limited

HOLD

Current Price

$12.58

Market Cap

3.8B

ML Signal

HOLD

Logo Denali Therapeutics Inc.

DNLI

Denali Therapeutics Inc.

HOLD

Current Price

$24.79

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLO
DNLI
Founded
2013
2013
Country
Uruguay
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.7B
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
DLO
DNLI
Price
$12.58
$24.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
14
Target Price
$17.25
$34.33
AVG Volume (30 Days)
1.9M
1.7M
Earning Date
05-14-2026
05-06-2026
Dividend Yield
1.45%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$41.00
N/A
Revenue Next Year
$26.98
$408.85
P/E Ratio
$22.27
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.81
$12.58
52 Week High
$16.78
$25.97

Technical Indicators

Market Signals
Indicator
DLO
DNLI
Relative Strength Index (RSI) 54.84 73.00
Support Level $11.93 $18.27
Resistance Level $12.99 N/A
Average True Range (ATR) 0.48 1.24
MACD 0.07 0.35
Stochastic Oscillator 79.30 82.36

Price Performance

Historical Comparison
DLO
DNLI

About DLO DLocal Limited

DLocal Ltd is focused on making the complex simple, redefining the online payment experience in emerging markets. Through its technology platform, One dLocal, the company enables world-wide enterprise merchants to get paid (pay-in) and to make payments (pay-out) online in a safe and efficient manner. The company earns revenue from fees charged to merchants in connection with payment processing services for cross-border and local payment transactions. The company operates in a single operating segment, which is payment processing. The company's geographical segments include Latin America and Non-Latin America, with a majority of its revenue being generated from Brazil in the Latin America region.

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Share on Social Networks: